Opinion|Videos|January 28, 2025
Addressing Potential Barriers to the Adoption of Afami-Cel Therapy
A panelist discusses how key barriers to broad afamitresgene autoleucel (afami-cel) adoption include manufacturing turnaround times, the need for specialized cell therapy centers, testing requirements, and coordination of lymphodepletion timing, though these challenges are being actively addressed through improved processes and infrastructure development.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the logistical or clinical barriers for broad adoption of afami-cel?
Advertisement
Related to this article
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5